CN114621109B - Synthesis method of apatamide and intermediate thereof - Google Patents

Synthesis method of apatamide and intermediate thereof Download PDF

Info

Publication number
CN114621109B
CN114621109B CN202111514273.4A CN202111514273A CN114621109B CN 114621109 B CN114621109 B CN 114621109B CN 202111514273 A CN202111514273 A CN 202111514273A CN 114621109 B CN114621109 B CN 114621109B
Authority
CN
China
Prior art keywords
compound
added
room temperature
water
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111514273.4A
Other languages
Chinese (zh)
Other versions
CN114621109A (en
Inventor
庞学海
霍海建
王颖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Yuanhua Pharmaceutical Technology Co ltd
Chengdu Easton Biopharmaceuticals Co Ltd
Original Assignee
Shanghai Yuanhua Pharmaceutical Technology Co ltd
Chengdu Easton Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yuanhua Pharmaceutical Technology Co ltd, Chengdu Easton Biopharmaceuticals Co Ltd filed Critical Shanghai Yuanhua Pharmaceutical Technology Co ltd
Publication of CN114621109A publication Critical patent/CN114621109A/en
Application granted granted Critical
Publication of CN114621109B publication Critical patent/CN114621109B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention belongs to the field of pharmaceutical chemical synthesis, and relates to two compounds, a preparation method thereof and application thereof in synthesis of apatamide. The method for preparing the apatamide has the advantages of simple process, easy operation, mild reaction conditions, high yield and contribution to realizing industrial production, and the use of thiophosgene with high toxicity is avoided.

Description

Synthesis method of apatamide and intermediate thereof
Technical Field
The invention belongs to the technical field of pharmaceutical chemistry synthesis, and particularly relates to two compounds, a preparation method thereof and application thereof in synthesis of apatamide. The invention also relates to a method for synthesizing apatamide.
Background
Apatamide (Apalutamide), chemical name: 4- (7- (6-cyano-5- (trifluoromethyl) pyridin-3-yl) -8-oxo-6-thioxo-5, 7-diazaspiro [3.4] oct-5-yl) -2-fluoro-N-methylbenzamide, the structural formula of which is shown as formula VII.
Apatamide as a nonsteroidal androgen receptor inhibitor developed by Aragon corporation of the united states is used to treat adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis.
At present, the preparation method of the apatamide generally comprises the steps of reacting 1-amino ring Ding Jiasuan with N-methyl-4-bromo-2-fluoro-benzamide to obtain 4- (1-carboxyl-cyclobutylamino) -2-fluoro-benzamide, and esterifying the 4- (1-carboxyl-cyclobutylamino) -2-cyano-3-trifluoromethyl pyridine ring to generate the apatamide. For example, patent CN 101454002 B,CN 108069869 A,CN 107501237 A,CN 108047200 A,CN 109988077A, but the preparation method has higher material cost, is difficult to stably supply, is unfavorable for industrialized mass production, has lower total yield of the route, generates more three wastes, has larger environmental pollution, uses thiophosgene with larger toxicity in some routes, and has larger potential safety hazard. Therefore, the searching of a novel preparation method of the apatamide with simple process, low production cost and small environmental pollution has very important practical significance.
Disclosure of Invention
A first object of the present invention is to provide a compound I having the following structure:
the present invention further provides a process for preparing compound I, comprising the steps of:
X is Cl, br or I.
Compound II is reacted with 1-amino ring Ding Jiasuan or a salt thereof in the presence of a catalyst, a base, and a reaction solvent to prepare compound I.
Wherein the molar ratio of the compound II to the 1-amino ring Ding Jiasuan or the salt thereof is 1:1.0-2.0. Preferably 1:1.2.
Wherein the catalyst is one or more selected from copper powder, cuprous iodide, cuprous bromide, cuprous chloride and cuprous oxide. Preferably copper iodide or a mixed catalytic system consisting of copper powder and copper iodide. More preferred are mixed catalytic systems having a molar ratio of copper powder to copper iodide of 1:1.
Wherein the molar ratio of the compound II to the catalyst is 1:0.1-0.3. Preferably 1:0.15.
Wherein the ligand of the catalyst is selected from dimethylglycine, proline or N, N' -dimethyl-1, 2-cyclohexanediamine. Dimethylglycine is preferred.
Wherein the molar ratio of the catalyst to the catalyst ligand is 1:1.0-1.5. Preferably 1:1.2.
Wherein the base is selected from inorganic bases including, but not limited to, potassium carbonate, sodium carbonate, cesium carbonate, lithium carbonate, potassium phosphate, potassium hydroxide, sodium hydroxide, and the like. Potassium carbonate is preferred.
Wherein the molar ratio of the compound II to the alkali is 1:2.5-3.5. Preferably 1:3.0.
Wherein the reaction solvent is a mixed solvent composed of an organic solvent and water, wherein the organic solvent is one or more selected from N, N-dimethylformamide, N-dimethylacetamide, dimethyl sulfoxide, N-methylpyrrolidone and water. Preferably, a mixed solvent of N, N-dimethylacetamide and water or a mixed solvent of N-methylpyrrolidone and water.
Wherein the mass ratio of the organic solvent to water in the mixed solvent is 1:0.10-0.20. Preferably 1:0.14.
Wherein the reaction temperature is 90-110 ℃. Preferably 95 ℃.
In some specific embodiments, compound II is reacted with 1-amino ring Ding Jiasuan or a salt thereof at 95 ℃ in a mixed catalytic system having a 1:1 molar ratio of copper powder to cuprous iodide, dimethylglycine as the catalyst ligand, potassium carbonate as the base, and a mixed solvent of N, N-dimethylformamide and water to form compound I.
A second object of the present invention is to provide a compound IV having the following structure:
r is C1-C6 alkyl, C1-C6 aryl or heteroaryl. Preferably methyl, ethylallyl or benzyl. More preferably methyl or ethyl.
The present invention further provides a process for preparing compound IV comprising the steps of:
R is C1-C6 alkyl, C1-C6 aryl or heteroaryl. Preferably methyl, ethyl, allyl or benzyl. More preferably methyl.
Compound I is reacted with RX '(X' is Cl, br or I) or ROH in the presence of an auxiliary reagent to prepare compound IV.
Wherein, when compound I is reacted with RX '(X' is Cl, br or I), the auxiliary reagent is selected from, but not limited to: triethylamine, pyridine, diisopropylethylamine, potassium carbonate, sodium carbonate, cesium carbonate, lithium carbonate. Potassium carbonate or cesium carbonate is preferred.
Wherein, when compound I is reacted with RX ' (X ' is Cl, br or I), the molar ratio of compound I to RX ' is 1:2.0-3.0, preferably 1:2.5; the molar ratio of compound I to auxiliary agent is 1:2.0-5.0, preferably 1:3.0.
Wherein, when compound I is reacted with ROH, the auxiliary reagent is selected from, but not limited to: thionyl chloride, oxalyl chloride, hydrochloric acid, sulfuric acid. Preferably thionyl chloride or oxalyl chloride.
Wherein the molar ratio of the compound I to the auxiliary reagent is 1:2.0-5.0, preferably 1:3.0.
Wherein the reaction temperature is 20-80 ℃, preferably 40-60 ℃.
In some specific embodiments, compound I is reacted with RX '(X' is Cl, br, or I) in the presence of potassium carbonate at 40-60℃to form compound IV. In some specific embodiments, compound I is reacted with ROH in the presence of thionyl chloride at 40-60 ℃ to form compound IV.
A third object of the present invention is to provide a process for preparing compound VI from compound IV and 5-isothiocyanato-2-cyano-3-trifluoromethylpyridine, which comprises the steps of:
R is C1-C6 alkyl, C1-C6 aryl or heteroaryl. Preferably methyl, ethyl, allyl or benzyl. More preferably methyl.
Compound iv is reacted with 5-isothiocyanato-2-cyano-3-trifluoromethylpyridine in the presence of an organic solvent to prepare compound VI.
Wherein the molar ratio of the compound IV to the 5-isothiocyanato-2-cyano-3-trifluoromethylpyridine is 1:1.3-2.0. Preferably 1:1.5.
Wherein the organic solvent is selected from one or more of N, N-dimethylformamide, N-dimethylacetamide, dimethyl sulfoxide, N-methylpyrrolidone, isopropyl acetate and toluene. N-methylpyrrolidone, N-dimethylacetamide or dimethylsulfoxide are preferred.
Wherein the reaction temperature is 80-120 ℃. Preferably 90-100 ℃.
In some specific embodiments, compound IV is reacted with 5-isothiocyano-2-cyano-3-trifluoromethylpyridine in N-methylpyrrolidone at 90-100deg.C to form compound VI.
The present invention provides a process for preparing compound VII apatamide from compound VI, comprising the steps of:
R is C1-C6 alkyl, C1-C6 aryl or heteroaryl. Preferably methyl, ethyl, allyl or benzyl. More preferably methyl.
Compound VI was prepared with methylamine reagent in the presence of organic solvent.
Among them, methylamine reagents include, but are not limited to, methylamine gas, aqueous methylamine solution, methanolic methylamine solution, ethanolic methylamine solution, tetrahydrofuran methylamine solution, methylamine hydrochloride, and the like. Aqueous methylamine solutions are preferred.
Wherein the molar ratio of the compound VI to the aqueous solution of methylamine is 1:8-12. Preferably 1:10.
Wherein the organic solvent is selected from one or more of N, N-dimethylformamide, N-dimethylacetamide, dimethyl sulfoxide, N-methylpyrrolidone, isopropyl acetate, tetrahydrofuran and acetonitrile. Tetrahydrofuran or acetonitrile are preferred.
Wherein the reaction temperature is 10-50 ℃. Preferably 20-30 ℃.
In some specific embodiments, compound VI is reacted with aqueous methylamine in tetrahydrofuran at 20-30 ℃ to form compound VII apatamide.
The invention provides a method for preparing VII apatamide, which comprises the following steps:
x is Cl, br or I;
R is C1-C6 alkyl, C1-C6 aryl or heteroaryl. Preferably methyl, allyl or benzyl. More preferably methyl.
1) The compound II, 1-amino ring Ding Jiasuan or salt thereof, potassium carbonate, dimethyl glycine, copper powder and cuprous iodide react in a mixed solvent of N, N-dimethylformamide and water at the temperature of 90-110 ℃ to generate a compound I;
2) The compound I and R-X' or R-OH undergo substitution or esterification reaction to obtain a compound IV;
3) The compound IV and 5-isothiocyanato-2-cyano-3-trifluoromethyl pyridine are subjected to ring closure to obtain a compound VI;
4) The compound VI and methylamine undergo ammonolysis reaction to obtain the compound VII apatamide.
The method adopts 4-bromo-2-fluorobenzoic acid as a raw material, and the target product apatamide is obtained through 4 steps of reactions; compared with the existing methods for preparing the apatamide, the method has the advantages of simple and easily purchased initial raw materials, lower cost, mild reaction conditions in each step, simple operation and high yield, and avoids the use of thiophosgene with higher toxicity; meanwhile, the purity of the product obtained by the preparation method is more than 99 percent, and the total yield is as high as 50 to 60 percent, so that the method is beneficial to realizing industrial production.
Detailed Description
The present invention is described in further detail below with reference to examples, but is not limited to the following examples, and any equivalents in the art, which are in accordance with the present disclosure, are intended to fall within the scope of the present invention.
EXAMPLE 1 preparation of Compound I4- (1-carboxy-cyclobutylamino) -2-fluoro-benzoic acid
Under the protection of inert gas at room temperature, 40ml of N, N-dimethylacetamide, 6.5ml of water, 5g of 4-bromo-2-fluorobenzoic acid, 5.26g of compound III, 1.06g of dimethylglycine, 0.44g of copper powder, 1.30g of cuprous iodide and 11.03g of potassium carbonate are sequentially added into a reaction bottle, and the temperature is raised to 90 ℃ for reaction for 20 hours. Cooled to room temperature, 100ml of water was added and stirred for 0.5 hour. Suction filtration, pH of the filtrate was adjusted to 3-4 with concentrated hydrochloric acid, and extraction was performed 4 times with 50ml of ethyl acetate. The organic phases were combined, washed with saturated brine and concentrated under reduced pressure to remove the organic solvent. To the residue was added 100ml of water, stirred at room temperature for 2 hours, and filtered to give a crude product of compound I. And (5) refluxing, pulping and purifying by acetonitrile, and drying. 5.40g of pure compound I (HPLC purity 97.32%, yield 93.4%) were obtained.
MS+[M+1]254.1。
1H NMR(400MHz,DMSO)δ12.49(s,2H),7.60(t,J＝8.3Hz,1H),7.43(s,1H),6.22(d,J＝8.3Hz,1H),6.00(d,J＝13.9Hz,1H),2.64–2.57(m,2H),2.30–2.07(m,2H),2.06–1.76(m,2H).13C NMR(101MHz,DMSO)δ175.4,165.0,164.9,161.9,152.3,133.2,108.4,105.3,98.6,58.8,30.4,14.8.
EXAMPLE 2 preparation of Compound I4- (1-carboxy-cyclobutylamino) -2-fluoro-benzoic acid
40Ml of N-methylpyrrolidone, 8.0ml of water, 5g of 4-bromo-2-fluorobenzol, 3.28g of compound III, 0.26g of proline, 0.15g of copper powder, 0.43g of cuprous iodide and 2.28g of sodium hydroxide are sequentially added into a reaction flask under the protection of inert gas at room temperature, and the mixture is heated to 110 ℃ for reaction for 20 hours. Cooled to room temperature, 100ml of water was added and stirred for 0.5 hour. Suction filtration, pH of the filtrate was adjusted to 3-4 with concentrated hydrochloric acid, and extraction was performed 4 times with 50ml of ethyl acetate. The organic phases were combined, washed with brine and concentrated under reduced pressure to remove the organic solvent. To the residue was added 100ml of water, stirred at room temperature for 2 hours, and filtered to give a crude product of compound I. And (5) refluxing, pulping and purifying by acetonitrile, and drying. 5.24g of pure compound I (HPLC purity 96.48%, yield 90.7%) were obtained.
EXAMPLE 3 preparation of Compound I4- (1-carboxy-cyclobutylamino) -2-fluoro-benzoic acid
Under the protection of inert gas at room temperature, 40ml of N, N-dimethylformamide, 3.8ml of water, 5g of 4-bromo-2-fluorobenzoic acid, 3.94g of compound III, 0.42g of dimethylglycine, 0.22g of copper powder, 0.65g of cuprous iodide and 10.40g of potassium carbonate are added into a reaction bottle in sequence, and the temperature is raised to 95 ℃ for reaction for 20 hours. Cooled to room temperature, 100ml of water was added and stirred for 0.5 hour. Suction filtration, pH of the filtrate was adjusted to 3-4 with concentrated hydrochloric acid, and extraction was performed 4 times with 50ml of ethyl acetate. The organic phases were combined, washed with brine and concentrated under reduced pressure to remove the organic solvent. To the residue was added 100ml of water, stirred at room temperature for 2 hours, and filtered to give a crude product of compound I. And (5) refluxing, pulping and purifying by acetonitrile, and drying. 5.31g of pure compound I (HPLC purity 96.85%, yield 91.9%) are obtained.
EXAMPLE 4 preparation of Compound I4- (1-carboxy-cyclobutylamino) -2-fluoro-benzoic acid
Under the protection of inert gas at room temperature, 40ml of N, N-dimethylacetamide, 6.5ml of water, 5g of compound II, 3.94g of compound III, 0.58g of N, N' -dimethyl-1, 2-cyclohexanediamine, 0.65g of cuprous iodide and 10.40g of potassium carbonate are added into a reaction bottle in sequence, and the temperature is raised to 95 ℃ for reaction for 20 hours. Cooled to room temperature, 100ml of water was added and stirred for 0.5 hour. Suction filtration, pH of the filtrate was adjusted to 3-4 with concentrated hydrochloric acid, and extraction was performed 4 times with 50ml of ethyl acetate. The organic phases were combined, washed with brine and concentrated under reduced pressure to remove the organic solvent. To the residue was added 100ml of water, stirred at room temperature for 2 hours, and filtered to give a crude product of compound I. And (5) refluxing, pulping and purifying by acetonitrile, and drying. 5.19g of pure compound I (HPLC purity 95.46%, yield 89.8%) were obtained.
EXAMPLE 5 preparation of Compound I4- (1-carboxy-cyclobutylamino) -2-fluoro-benzoic acid
400Ml of N, N-dimethylacetamide, 65ml of water, 50g of a compound II, 39.4g of a compound III, 4.2g of dimethylglycine, 2.2g of copper powder, 6.5g of cuprous iodide and 104.0g of potassium carbonate are sequentially added into a reaction bottle at room temperature under the protection of inert gas, and the mixture is heated to 95 ℃ for reaction for 20 hours. Cooled to room temperature, 1000ml of water is added and stirred for 0.5 hour. Suction filtration, pH of the filtrate was adjusted to 3-4 with concentrated hydrochloric acid, and extraction was performed 4 times with 500ml of ethyl acetate. The organic phases were combined, washed with brine and concentrated under reduced pressure to remove the organic solvent. 1000ml of water was added to the residue, stirred at room temperature for 2 hours, and filtered to give a crude product of compound I. And (5) refluxing, pulping and purifying by acetonitrile, and drying. 54.63g of pure compound I (HPLC purity 98.11%, yield 94.5%) are obtained.
EXAMPLE 6 preparation of the Compound 4- (1-methoxycarbonyl-cyclobutylamino) -2-fluoro-benzoic acid methyl ester
500Ml of methanol and 50g of compound I are added into a reaction flask under the protection of inert gas at room temperature, and 51.73g of oxalyl chloride is added dropwise at 5-15 ℃. The reaction was carried out at 40℃for 5 hours. The organic solvent was concentrated under reduced pressure, 500ml of water was added to the residue, which was stirred at room temperature for 2 hours, filtered and dried to give 50.10g of methyl 4- (1-methoxycarbonyl-cyclobutylamino) -2-fluoro-benzoate (HPLC purity 98.72%, yield 90.2%).
MS+[M+1]282.2。
1H NMR(400MHz,DMSO)δ7.70–7.46(m,2H),6.22(d,J＝8.3Hz,1H),6.01(d,J＝14.0Hz,1H),3.73(s,3H),3.63(s,3H),2.72–2.55(m,2H),2.28–2.11(m,2H),2.11–1.79(m,2H).13C NMR(101MHz,DMSO)δ174.1,164.2,163.9,161.7,152.2,133.0,108.5,104.5,98.7,58.9,52.39,51.4,30.5,14.8.
EXAMPLE 7 preparation of the Compound 4- (1-methoxycarbonyl-cyclobutylamino) -2-fluoro-benzoic acid methyl ester
100Ml of methanol and 10g of compound I are added into a reaction bottle under the protection of inert gas at room temperature, and 23.50g of thionyl chloride is added dropwise at 5-15 ℃. The reaction was carried out at 60℃for 2 hours. The organic solvent was concentrated under reduced pressure, 100ml of water was added to the residue, and the mixture was stirred at room temperature for 2 hours, filtered and dried to give 10.95g of methyl 4- (1-methoxycarbonyl-cyclobutylamino) -2-fluoro-benzoate (HPLC purity 98.36%, yield 98.6%).
EXAMPLE 8 preparation of the Compound 4- (1-ethoxycarbonyl-cyclobutylamino) -2-fluoro-benzoic acid ethyl ester
100Ml of ethanol and 10g of compound I are added into a reaction bottle under the protection of inert gas at room temperature, and 14.10g of thionyl chloride is added dropwise at 5-15 ℃. The reaction was carried out at 60℃for 2 hours. The organic solvent was concentrated under reduced pressure, 100ml of water was added to the residue, and the mixture was stirred at room temperature for 2 hours, filtered and dried to give 10.46g of 4- (1-ethoxycarbonyl-cyclobutylamino) -2-fluoro-benzoic acid ethyl ester (purity by HPLC: 97.25%, yield: 94.2%).
EXAMPLE 9 preparation of the Compound 4- (1-methoxycarbonyl-cyclobutylamino) -2-fluoro-benzoic acid methyl ester
280Ml of DMF, 90.07g of cesium carbonate and 35g of compound I are added to a reaction flask at room temperature under the protection of inert gas, and 39.25g of methyl iodide is added dropwise at 5-15 ℃. The reaction was carried out at 40℃for 5 hours. Cooling to room temperature, adding the system into 1400ml of water, stirring at room temperature for 2 hours, filtering, and drying to obtain 35.46g of compound 4- (1-methoxycarbonyl-cyclobutylamino) -2-fluoro-benzoic acid methyl ester (HPLC purity 96.36%, yield 91.2%).
EXAMPLE 10 preparation of the Compound 4- (1-methoxycarbonyl-cyclobutylamino) -2-fluoro-benzoic acid methyl ester
Under the protection of inert gas at room temperature, 280ml of DMF, 95.37g of potassium carbonate and 35g of compound I are added into a reaction bottle, and 58.87g of methyl iodide is added dropwise at 5-15 ℃. The reaction was carried out at 60℃for 3 hours. Cooling to room temperature, adding the system into 1400ml of water, stirring at room temperature for 2 hours, filtering, and drying to obtain 35.89g of compound 4- (1-methoxycarbonyl-cyclobutylamino) -2-fluoro-benzoic acid methyl ester (HPLC purity 97.57%, yield 92.3%).
EXAMPLE 11 preparation of Compound I V methyl 4- (1-methoxycarbonyl-cyclobutylamino) -2-fluoro-benzoate
1000Ml of methanol and 100g of compound I are added into a reaction bottle under the protection of inert gas at room temperature, and 141.0g of thionyl chloride is added dropwise at 5-15 ℃. The reaction was carried out at 50℃for 2 hours. The organic solvent was concentrated under reduced pressure, 100ml of water was added to the residue, and the mixture was stirred at room temperature for 2 hours, filtered and dried to give 108.7g of methyl 4- (1-methoxycarbonyl-cyclobutylamino) -2-fluoro-benzoate (HPLC purity 98.88%, yield 97.9%).
EXAMPLE 12 preparation of the Compound 4- (7- (6-cyano-5- (trifluoromethyl) pyridin-3-yl) -8-oxo-6-thioxo-5, 7-diazaspiro [3.4] oct-5-yl) -2-fluoro-N-methylbenzoic acid methyl ester
45Ml of dimethyl sulfoxide, 45g of compound IV and 47.66g of 5-isothiocyanato-2-cyano-3-trifluoromethylpyridine are added into a reaction flask at room temperature under the protection of inert gas, and the temperature is raised to 80 ℃ for reaction for 24 hours. 180ml of ethyl acetate was added, 180ml of water was used for extraction and separation, and the aqueous phase was extracted twice with 90ml of ethyl acetate. The organic phases were combined, washed with saturated brine, concentrated under reduced pressure to remove the organic solvent, and 90ml of isopropanol was added to the residue to crystallize, which was filtered and dried to give 52.35g of the compound methyl 4- (7- (6-cyano-5- (trifluoromethyl) pyridin-3-yl) -8-oxo-6-thioxo-5, 7-diazaspiro [3.4] oct-5-yl) -2-fluoro-N-methylbenzoate (HPLC purity 99.12%, yield 68.4%).
MS+[M+1]479.2。
1H NMR(400MHz,DMSO)δ9.21(d,J＝1.9Hz,1H),8.74(d,J＝1.9Hz,1H),8.14(t,J＝8.3Hz,1H),7.55(dd,J＝11.0,1.8Hz,1H),7.46(dd,J＝8.3,1.8Hz,1H),3.91(s,3H),2.74–2.58(m,2H),2.58–2.41(m,2H),2.03–1.91(m,1H),1.64–1.54(m,1H).13C NMR(101MHz,DMSO)δ179.6,174.3,163.3,159.7,153.4,140.8,135.5,133.0,129.0,126.6,122.9,119.3,119.0,114.2,67.7,52.7,31.1,13.4.
EXAMPLE 13 preparation of the Compound 4- (7- (6-cyano-5- (trifluoromethyl) pyridin-3-yl) -8-oxo-6-thioxo-5, 7-diazaspiro [3.4] oct-5-yl) -2-fluoro-N-methylbenzoic acid methyl ester
45Ml of N, N-dimethylacetamide, 45g of compound IV and 73.33g of 5-isothiocyanato-2-cyano-3-trifluoromethylpyridine were added to a reaction vessel at room temperature under the protection of inert gas, and the reaction was carried out at 120℃for 20 hours. 180ml of ethyl acetate was added, 180ml of water was used for extraction and separation, and the aqueous phase was extracted twice with 90ml of ethyl acetate. The organic phases were combined, washed with saturated brine, concentrated under reduced pressure to remove the organic solvent, and 90ml of isopropanol was added to the residue to crystallize, which was filtered and dried to give 54.65g of the compound methyl 4- (7- (6-cyano-5- (trifluoromethyl) pyridin-3-yl) -8-oxo-6-thioxo-5, 7-diazaspiro [3.4] oct-5-yl) -2-fluoro-N-methylbenzoate (HPLC purity 98.98%, yield 71.4%).
EXAMPLE 14 preparation of the Compound 4- (7- (6-cyano-5- (trifluoromethyl) pyridin-3-yl) -8-oxo-6-thioxo-5, 7-diazaspiro [3.4] oct-5-yl) -2-fluoro-N-methylbenzoic acid methyl ester
45Ml of NMP, 45g of compound IV and 55g of 5-isothiocyanato-2-cyano-3-trifluoromethylpyridine are added into a reaction flask at room temperature under the protection of inert gas, and the mixture is heated to 95 ℃ for reaction for 20 hours. 180ml of ethyl acetate was added, 180ml of water was used for extraction and separation, and the aqueous phase was extracted twice with 90ml of ethyl acetate. The organic phases were combined, washed with saturated brine, concentrated under reduced pressure to remove the organic solvent, and 90ml of isopropanol was added to the residue to crystallize, which was filtered and dried to give the compound methyl 4- (7- (6-cyano-5- (trifluoromethyl) pyridin-3-yl) -8-oxo-6-thioxo-5, 7-diazaspiro [3.4] oct-5-yl) -2-fluoro-N-methylbenzoate 60.24g (HPLC purity 99.24%, yield 78.7%).
EXAMPLE 15 preparation of Compound VII (apatamide)
102Ml of tetrahydrofuran and 34g of the compound VI are introduced into a reaction flask at room temperature under the protection of inert gas, and 55.2g (content: about 40%) of an aqueous methylamine solution is added dropwise at 5-15 ℃. The reaction was carried out at 50℃for 16 hours. The organic solvent was concentrated under reduced pressure, 100ml of isopropanol was added to the residue to crystallize, and the crystals were filtered and dried to obtain 28.16g of compound VII apatamide (HPLC purity 99.65%, yield 83.0%).
MS+[M+1]478.1,
1H NMR(400MHz,DMSO)δ9.21(d,J＝1.9Hz,1H),8.75(d,J＝1.9Hz,1H),8.49(d,J＝4.3Hz,1H),7.83(t,J＝8.0Hz,1H),7.47(dd,J＝10.5,1.8Hz,1H),7.38(dd,J＝8.1,1.8Hz,1H),2.81(d,J＝4.3Hz,3H),2.73–2.57(m,2H),2.57–2.35(m,2H),1.94-1.99(m,1H),1.70–1.45(m,1H).13C NMR(101MHz,DMSO)δ174.3,163.4,153.4,135.5,133.2,131.1,126.4,125.4,118.3,67.6,31.1,26.2,13.4.
EXAMPLE 16 preparation of Compound VII (apatamide)
102Ml of acetonitrile and 34g of compound VI are added to a reaction flask at room temperature under the protection of inert gas, and 55.2g (content about 40%) of aqueous methylamine solution is added dropwise at 5-15 ℃. The reaction was carried out at 10℃for 36 hours. The organic solvent was concentrated under reduced pressure, 100ml of isopropanol was added to the residue to crystallize, and the crystals were filtered and dried to obtain 27.95g of compound VII (HPLC purity 99.68%, yield 82.4%).
EXAMPLE 17 preparation of Compound VII (apatamide)
102Ml of tetrahydrofuran and 34g of the compound VI are introduced into a reaction flask at room temperature under the protection of inert gas, and 55.2g (content: about 40%) of an aqueous methylamine solution is added dropwise at 5-15 ℃. The reaction was carried out at 25℃for 20 hours. The organic solvent was concentrated under reduced pressure, 100ml of isopropanol was added to the residue to crystallize, and the crystals were filtered and dried to obtain 28.04g of compound VII (HPLC purity 99.36%, yield 82.6%).

Claims (1)

1. A process for the preparation of compound VII apatamide, characterized in that it comprises the steps of:
Step 1): ，
Under the protection of inert gas at room temperature, 400ml of N, N-dimethylacetamide, 65ml of water, 50g of compound II, 39.4g of compound III, 4.2g of dimethylglycine, 2.2g of copper powder, 6.5g of cuprous iodide and 104.0g of potassium carbonate are sequentially added into a reaction bottle, and the temperature is raised to 95 ℃ for reaction for 20 hours; cooling to room temperature, adding 1000ml of water, stirring for 0.5 hour, filtering, adjusting the pH of the filtrate to 3-4 with concentrated hydrochloric acid, extracting with 500ml of ethyl acetate for 4 times, combining organic phases, washing with brine, concentrating under reduced pressure to remove organic solvent, adding 1000ml of water into the residue, stirring for 2 hours at room temperature, filtering to obtain a crude product of the compound I, refluxing with acetonitrile, pulping, purifying, drying to obtain 54.63g of the pure compound I, wherein the HPLC purity is 98.11%, and the yield is 94.5%;
Step 2): ，
Under the protection of inert gas at room temperature, adding 100ml of methanol and 10g of compound I into a reaction bottle, and dropwise adding 23.50g of thionyl chloride at 5-15 ℃; heating to 60deg.C for 2 hr, concentrating under reduced pressure to remove organic solvent, adding water 100ml into the residue, stirring at room temperature for 2 hr, filtering, and drying to obtain compound IV 10.95g with HPLC purity 98.36% and yield 98.6%;
step 3): ，
Under the protection of inert gas at room temperature, 45ml of NMP, 45g of compound IV and 55g of compound V are added into a reaction bottle, the temperature is raised to 95 ℃ for reaction for 20 hours, 180ml of ethyl acetate is added, 180ml of water is used for extraction and separation, 90ml of ethyl acetate is used for extraction of water phase for two times, organic phases are combined, saturated saline is used for washing, the organic solvent is concentrated under reduced pressure, 90ml of isopropanol is added into the residue for crystallization, and the mixture is filtered and dried to obtain 60.24g of compound VI, the HPLC purity is 99.24%, and the yield is 78.7%;
Step 4): ，
under the protection of inert gas at room temperature, 102ml of tetrahydrofuran and 34g of compound VI are added into a reaction bottle, 55.2g of methylamine water solution with the content of about 40 percent is added dropwise at the temperature of 5-15 ℃, the temperature is raised to 50 ℃ for reaction for 16 hours, the organic solvent is concentrated under reduced pressure, 100ml of isopropanol is added into the residue for crystallization, and the residue is filtered and dried to obtain 28.16g of compound VII with the HPLC purity of 99.65 percent and the yield of 83.0 percent.
CN202111514273.4A 2020-12-14 2021-12-13 Synthesis method of apatamide and intermediate thereof Active CN114621109B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020114747970 2020-12-14
CN202011474797 2020-12-14

Publications (2)

Publication Number Publication Date
CN114621109A CN114621109A (en) 2022-06-14
CN114621109B true CN114621109B (en) 2024-04-26

Family

ID=81898701

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111514273.4A Active CN114621109B (en) 2020-12-14 2021-12-13 Synthesis method of apatamide and intermediate thereof

Country Status (1)

Country Link
CN (1) CN114621109B (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108553A (en) * 2014-12-19 2017-08-29 阿拉贡药品公司 The method for preparing Diarylthiohydantoin compounds
CN107954936A (en) * 2016-10-17 2018-04-24 成都海创药业有限公司 A kind of method for preparing deuterated Imidazole diketone compound
CN108976171A (en) * 2018-08-27 2018-12-11 长沙泽达医药科技有限公司 Compound, composition and its purposes in medicine preparation
CN109694330A (en) * 2017-10-24 2019-04-30 乳源瑶族自治县东阳光生物科技有限公司 A kind of preparation method of acid

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2557235C1 (en) * 2014-07-08 2015-07-20 Александр Васильевич Иващенко Substituted 2-thioxo-imidazolidin-4-one, and spiroanalogues thereof, anticancer active ingredient, pharmaceutical composition, medicinal product, method of treating prostate cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108553A (en) * 2014-12-19 2017-08-29 阿拉贡药品公司 The method for preparing Diarylthiohydantoin compounds
CN107954936A (en) * 2016-10-17 2018-04-24 成都海创药业有限公司 A kind of method for preparing deuterated Imidazole diketone compound
CN109694330A (en) * 2017-10-24 2019-04-30 乳源瑶族自治县东阳光生物科技有限公司 A kind of preparation method of acid
CN108976171A (en) * 2018-08-27 2018-12-11 长沙泽达医药科技有限公司 Compound, composition and its purposes in medicine preparation

Also Published As

Publication number Publication date
CN114621109A (en) 2022-06-14

Similar Documents

Publication Publication Date Title
JP6061158B2 (en) Synthesis intermediate of 6- (7-((1-aminocyclopropyl) methoxy) -6-methoxyquinolin-4-yloxy) -N-methyl-1-naphthamide, or a pharmaceutically acceptable salt thereof, and its use
JP7038263B2 (en) Method for Producing Morpholine Quinazoline Compound and its Intermediate
CN110590635A (en) Preparation method of levetiracetam and intermediate thereof
CN103880830B (en) Synthesis method of azilsartan
CN110950765A (en) Preparation method of terbutaline sulfate
CN114805314A (en) Synthesis method of Ensaitevir
CN107531672A (en) Prepare the chemical technology of pyrimidine derivatives and its intermediate
CN109988077A (en) A kind of synthetic method and intermediate of A Palu amine
CN110305018A (en) A kind of preparation method of the bromo- 2- fluoronitrobenzene of 3-
CN112028819B (en) Organic ligand compound of tetraphenyl ethylene terpyridine, coordination supermolecule, preparation and application thereof
CN114621109B (en) Synthesis method of apatamide and intermediate thereof
CN104768936A (en) Enzalutamide polymorphic forms and its preparation
CN112939814B (en) Preparation method of deuterated dacarbazine intermediate
CN107629039B (en) The preparation method and intermediate of deuterated acrylamide
CN111646936A (en) Process for producing aromatic ether compound
CN106748725B (en) preparation method of 4-chloro-2-fluoro-phenylpropionic acid
CN111187197B (en) Synthesis method of Tezacaftor intermediate
CN111747879A (en) Large-process synthesis method of erexib
CN114524802B (en) Synthesis method of quinoline compound
WO2023020531A1 (en) Method for synthesizing 5,8-diamino-3,4-dihydro-2h-1-naphthalenone and intermediate compound used therein
CN104098556A (en) Novel synthetic process for rivaroxaban
CN108558862B (en) Synthetic method and intermediate of anti-leukemia cancer cell active molecule
CN113087648B (en) Synthesis method for improving purity of fludioxonil
CN111100111B (en) Method for preparing benzothiophene derivative
CN110078674B (en) Preparation method of 2-alkyl amino pyrimidone

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240320

Address after: No. 8 Xiyuan Avenue, High tech Zone, Chengdu, Sichuan Province, 611700

Applicant after: Chengdu Easton Biopharmaceuticals Co.,Ltd.

Country or region after: China

Applicant after: Shanghai Yuanhua Pharmaceutical Technology Co.,Ltd.

Address before: 610200 Tianfu international biological city, Shuangliu District, Chengdu, Sichuan Province (No. 18, Section 2, biological city middle road, Shuangliu District)

Applicant before: Chengdu shuoder Pharmaceutical Co.,Ltd.

Country or region before: China

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant